Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques

Analytical Services

Targeting accelerated progress at the IPAC-RS Nasal Innovation Forum 2025

Explore how Nanopharm presented strategies for accelerating patient-centric nasal product development at the IPAC-RS Nasal Innovation Forum 2025. Dive into key insights on regulatory science, advanced bioequivalence methods, and targeted drug delivery.

December 3, 2025 No Comments

Inhalation

Aligning Alternative Bioequivilence with U.S. FDA: Advancing aerosol dose collection to enhance in vitro dissolution studies

Discover how Nanopharm’s DissoHale system advances aerosol dose collection and dissolution testing to support FDA-aligned alternative bioequivalence for OIDPs.

December 3, 2025 No Comments

Analytical Services

GDUFA: FDA adds further weight to modelling and simulation’s role in bioequivalence

GDUFA 2026: FDA strengthens role of modeling & simulation for inhaled generic drug bioequivalence. Learn how this shift enhances efficiency for OINDP development.

November 6, 2025 No Comments

About Us

Product Development

Analytical Services

In-Silico Modeling

Regulatory

Nasal

Inhalation

Inhaled Biologics

Generics & Lifecycle Management

Resources

03 Dec 2025